Subtype
Uterine Corpus Neoplasm
CI-CAN-00007035Explore in graph →
Non-malignant451 active trials4 approved drugs28 evidence items
- NCIt
- C6300
Loading cancer entity…
Subtype
CI-CAN-00007035Explore in graph →
Clinical trials
1,714 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05603910 | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | recruiting | Phase 1 | 18 | Aaron WolfsonOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06096688 | Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | recruiting | — | 1,120 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 3, 2026 |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT07730970 | Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES Hysterectomy(vNOTES_NMBDIET) | recruiting | N/A | 160 | Fatih Sultan Mehmet Training and Research HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03538665 | The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons(DETECT) | recruiting | — | 1,700 | University of Alabama at BirminghamOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07200466 | Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation(ENDORISK-I) | recruiting | N/A | 735 | Radboud University Medical CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07022483 | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | recruiting | Phase 3 | 710 | Daiichi SankyoINDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 132 | MOMA TherapeuticsINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT06143631 | Prescription of Letrozole for Uterine Myoma(PLUM) | recruiting | Phase 4 | 140 | University of California, San FranciscoOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | recruiting | Phase 1 | 63 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06476808 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | recruiting | Phase 1 | 240 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 20, 2026 | clinicaltrials |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | recruiting | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07702799 | Low-Residue Diet Versus Rectal Enema Before Laparoscopic Surgery for Endometrial Cancer | recruiting | N/A | 100 | Mahmut YassaOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | recruiting | Phase 2 | 270 | Corcept TherapeuticsINDUSTRY | 8 | Jul 16, 2026 | clinicaltrials |
| NCT07209449 | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | recruiting | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07220512 | The Better, Harder, Faster, Stronger Study | recruiting | — | 35 | Wake Forest University Health SciencesOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07622901 | Fasting InTervention for Endometrial Cancer(FIT-ENDO) | recruiting | N/A | 42 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma(EV-4-EC) | recruiting | Phase 2 | 12 | William BradleyOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07527143 | Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer | recruiting | — | 25 | Mayo ClinicOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07690540 | DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER(iDEA) | recruiting | N/A | 510 | European Institute of OncologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07643012 | Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer(ADAPT-EC) | recruiting | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03832361 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | recruiting | Phase 2 | 50 | Alessandro SantinOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05691010 | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | recruiting | Early Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07046923 | A Study of LY4175408 in Participants With Advanced Cancer | recruiting | Phase 1 | 240 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT03675893 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07220239 | Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome(SCREEN-CUP) | recruiting | N/A | 25 | Jessica D. St. Laurent, MDOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 178 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05819892 | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07107334 | A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05247268 | Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer | recruiting | Phase 2 | 104 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06914297 | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC | recruiting | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06024109 | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy(BARHYSTER) | recruiting | — | 132 | Aesculap AGINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | recruiting | Phase 2 | 80 | MacroGenicsINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2026source: clinicaltrials